



DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty members have indicated that they do not have any relevant financial relationships with ineligible companies* to disclose and have indicated that their presentation or discussion will not include off-label or unapproved product usage.

Scott Elman, M.D.
Richa Gupta, M.D., MPH
Margaret Johnson, M.D.

Warren L. Kupin, M.D., FACP
Emerson Carvalho Perin, M.D., Ph.D.,
FACC

Michael B. Phillips, M.D., FACP
David D. Thiel, M.D.
Benjamin Wang, M.D.

The following faculty members have indicated that they do not have any relevant financial relationships with ineligible companies* to disclose and have indicated that their presentation or discussion will include off-label or unapproved product usage.

Larry M. Bush, M.D., FACP, FIDSA

Maria Hurtado Andrade, M.D., Ph.D.

Michael Blaha, M.D., faculty for this educational activity, is a consultant for Novartis Pharmaceuticals, Roche Holding AG Pharmaceutical, 89Bio Inc, Vectura Group Pharmaceutical, Boehringer Ingelheim Pharmaceutical, and Bayer Pharmaceuticals, Novo Nordisk Pharmaceutical, Amgen Biotechnology. Dr. Blaha receives grant and research support from Bayer Pharmaceuticals, Novo Nordisk Pharmaceutical, Amgen Biotechnology and is an advisor for Kowa Pharmaceutical, Emocha Health. Dr. Blaha has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Olga Fermo, M.D., faculty for this educational activity, is a consultant for Klick Health and has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Gregory Poland, M.D., faculty for this educational activity, is a consultant for AiZtech; Emergent Biosolutions; GlaxoSmithKline; Invivyd; Janssen GS, LLC; Merck & Co. Inc.; Moderna; Novavax; Syneos Health. Dr. Poland has indicated that the presentation or discussion will not include off-label or unapproved product usage.

K. Rajender Reddy, M.D., faculty for this educational activity, receives grant/ research support from Mallinckrodt, Grifols, Sequana, BMS, Intercept, Exact Sciences, HCCTARGET, NASH-TARGET, BioVie. Dr. Reddy is also an advisor for Spark Therapeutics, Novo Nordisk Pharmaceuticals, Mallinckrodt, Genfit Biotechnology. Dr. Reddy has indicated that the presentation or discussion will not include off-label or unapproved product usage.

John F. Rubin, M.D., FACP, director for this educational activity, indicated that he is a shareholder in Astrazeneca and Bristol Myers Squibb.

Amaal Starling, M.D., faculty for this educational activity, is a consultant for AbbVie, Allergan, Amgen, Axsome Therapeutics, Everyday Health, Lundbeck, Med-IQ, Medscape, NeuroIief, Satsuma, WebMD. Dr. Poland has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Robert M. Wachter, M.D., faculty for this educational activity, is an advisor for Curai Health, Forward Health. Dr. Wachter has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Michael B. Wallace, M.D., faculty for this educational activity, is an advisor for Verily, Boston Scientific, and Medtronic. Dr. Wallace has indicated that the presentation or discussion will not include off-label or unapproved product usage.

All of the relevant financial relationships listed for these individuals have been mitigated.

Other individuals involved in planning, content review, approval, or moderating for this educational activity have no relevant financial relationships to disclose with ineligible companies*.

**Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*